Back

Experts provide an overview on the management of inflammatory bowel disease using biologics and discussing their safety and efficacy data presented at the DDW Virtual 2021.

Optimizing Treatment Strategies to Manage Inflammatory Bowel Disease

Episodes

Specialty:

All

Year:

All

Panel of Inflammatory Bowel Disease Experts

EP. 1: Risk Factors Associated With Inflammatory Bowel Disease

ByRemo Panaccione, MD, FRCPC,Jessica Allegretti, MD, MPH,Edward Loftus Jr., MD,William Sandborn, MD

August 19th 2021

Expert gastroenterologists review the pathophysiology of inflammatory bowel disease (IBD) along with the associated risk factors.

EP. 2: Incidence and Prevalence of Inflammatory Bowel Disease

ByRemo Panaccione, MD, FRCPC,Jessica Allegretti, MD, MPH,Edward Loftus Jr., MD,William Sandborn, MD

August 19th 2021

Effect of age, gender, racial, and socioeconomic disparities on the incidence and prevalence of inflammatory bowel disease (IBD).

EP. 3: QoL of Patients With Inflammatory Bowel Disease

ByRemo Panaccione, MD, FRCPC,Edward Loftus Jr., MD,William Sandborn, MD

August 26th 2021

Expert opinions on the effect of the progressive, relapsing nature of inflammatory bowel disease on a patients’ quality of life.

EP. 4: Diagnosing Patients With Inflammatory Bowel Disease

ByRemo Panaccione, MD, FRCPC,Jessica Allegretti, MD, MPH,Edward Loftus Jr., MD,William Sandborn, MD

August 26th 2021

Panel of gastroenterologists share their perspectives regarding the diagnostic work-up for patients who may have symptoms suggestive of IBD.

EP. 5: Treatment Goals and Guidelines for Ulcerative Colitis and Crohn’s Disease

ByRemo Panaccione, MD, FRCPC,Jessica Allegretti, MD, MPH,Edward Loftus Jr., MD,William Sandborn, MD

September 2nd 2021

A panel of experts discuss the latest guidelines and how they make a treatment decision for patients with ulcerative colitis and Crohn’s disease.

EP. 6: Patient Factors to be Considered When Choosing Therapy for IBD

ByRemo Panaccione, MD, FRCPC,Jessica Allegretti, MD, MPH,William Sandborn, MD,Edward Loftus Jr., MD

September 2nd 2021

Important patient factors to consider other than severity of disease when choosing a therapeutic agent for inflammatory bowel disease.

EP. 7: IBD Treatment Options for Patients With Low-Risk Disease

ByRemo Panaccione, MD, FRCPC,Edward Loftus Jr., MD,William Sandborn, MD,Jessica Allegretti, MD, MPH

September 9th 2021

Initial IBD therapy for a patient with low-risk disease and measuring treatment response on initial therapy.

EP. 8: IBD Treatment: Approach in Moderate- to High-Risk Disease

ByRemo Panaccione, MD, FRCPC,William Sandborn, MD,Jessica Allegretti, MD, MPH

September 10th 2021

Expert gastroenterologists share their perspectives regarding overall treatment approach in a patient with moderate- to high-risk inflammatory bowel disease.

EP. 9: Surgical Intervention in IBD

ByRemo Panaccione, MD, FRCPC,Jessica Allegretti, MD, MPH,Edward Loftus Jr., MD,William Sandborn, MD

September 16th 2021

Indications for surgery in treating patients for ulcerative colitis (UC) and Crohn disease.

EP. 10: Biologics Used in the Treatment of IBD

ByRemo Panaccione, MD, FRCPC,William Sandborn, MD,Edward Loftus Jr., MD,Jessica Allegretti, MD, MPH

September 16th 2021

A panel of experts share their experiences with the use of biologics for the treatment of inflammatory bowel diseases (IBDs).

EP. 11: Ustekinumab and Vedolizumab in Patients With Crohn Disease

ByRemo Panaccione, MD, FRCPC,Edward Loftus Jr., MD,William Sandborn, MD

September 23rd 2021

Edward Loftus Jr, MD, and William Sandborn, MD, review the 5-year remission data from the IM-UNITI trial for ustekinumab and post hoc analysis from the GEMINI 2 trial for vedolizumab in patients with Crohn disease.

EP. 12: SEAVUE: Ustekinumab vs Adalimumab in Crohn Disease

ByWilliam Sandborn, MD,Remo Panaccione, MD, FRCPC,Jessica Allegretti, MD, MPH,Edward Loftus Jr., MD

September 23rd 2021

Details of the head-to-head SEAVUE study of ustekinumab vs adalimumab for induction and maintenance therapy in patients with moderate to severe Crohn disease.